Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Hello there! 👋 I'm Luca, a BI Developer with a passion for all things data, Proficient in Python, SQL and Power BI ...

Fibonacci sequences are sequences of numbers whose first two elements are 0, 1, and such that, starting from the third number, every element of the sequence is the sum of the previous two. They are of ...

Hi, I have been using lsp-ai so far successfully with Ollama, but now wanted to try Gemini - since the free tier is quite generous. I am having a weird problem though, where the \n characters are ...